Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells
Speaker: Tony Brown Moderator: Kristine R. Crews
Online live: May 07, 2024 11:00 AM EST Posted: May 27, 2024 Views: 6727
Q&AAbstract
Acute lymphoblastic leukemia (ALL) presents as a complex disease encompassing diverse genomic subtypes with varying treatment responses and outcomes. Despite significant advancements, challenges persist, particularly in addressing treatment resistance and relapse, highlighting the urgent need for personalized therapeutic strategies.
Functional precision medicine approaches, integrating drug sensitivity profiling and genomic testing, offer promising avenues towards tailored treatment solutions. In this webinar, we introduce an innovative ex vivo drug sensitivity imaging-based platform tailored for primary ALL cells. Leveraging fluorescence imaging and mesenchymal stromal cell co-culture, this high-throughput assay enables the assessment of individual drug sensitivity profiles, overcoming previous limitations in cell count requirements and assay duration. By correlating drug sensitivity data with patient genomic profiles, attendees will explore the potential for subtype-specific therapeutic opportunities and actionable target discovery in ALL.
Highlights:
1. Understanding ALL Complexity and challenges in ALL treatment
2. Introduction of an ex vivo Drug Sensitivity Imaging-based Platform
3. Correlating Drug Sensitivity with Genomics
4. Implications for Precision Oncology
Speaker
Tony Brown, Ph.D.
Lead Researcher, St. Jude Children’s Research Hospital
Anthony Brown is a lead researcher in the Pharmacotyping Resource at St. Jude Children’s Research Hospital. Anthony received his Ph.D. in Cancer an...
View more 
Moderator
Kristine R. Crews, Pharm.D.
Director of Research Operations, St. Jude Children's Research Hospital
Dr. Kristine Crews, PharmD, BCPS, is a renowned expert in pharmacokinetics and pharmacogenomics. She currently serves as Associate Director of the ...
View more
References
Rowland, L., Smart, B., Brown, A., Dettorre, G. M., Gocho, Y., Hunt, J., Yang, W., Yoshimura, S., Reyes, N., Du, G., John, A., Maxwell, D., Stock, W., Kornblau, S., Relling, M. V., Inaba, H., Pui, C. H., Bourquin, J. P., Karol, S. E., Mullighan, C. G., Evans, W. E., Yang, J. J. and Crews, K. R. (2023). Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio-protocol 13(15): e4731. DOI: 10.21769/BioProtoc.4731.
Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 Mar;1(3):329-344. doi: 10.1038/s43018-020-0037-3. Epub 2020 Mar 9. PMID: 32885175; PMCID: PMC7467080.
Do you have a question about this webinar?
Post your question, and we'll invite the webinar speaker to respond. You're welcome to join the discussion by answering or commenting on questions ( Note: Not all questions, especially those not directly relevant to the webinar topic, may be answered by the speaker. ).
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question.
Post a Question17 Q&A
Nov 19, 2025
Oct 15, 2025
Sep 9, 2025
